Senior Counsel Brian McCaslin spoke at the MCLE program titled, “Cutting Edge Life Sciences Law & Practice.”
The life sciences industry-biotech, pharma, medical devices, bioinformatics, specialized life sciences manufacturing-in Massachusetts has been, and is expected to be for years to come, a key driver of economic growth. Lawyers in firms with life sciences clients, in-house counsel at life sciences companies, and lawyers who represent clients investing in life sciences companies need to be current on the latest developments affecting the industry.
This intermediate-to-advanced level program addresses current developments and issues affecting the life sciences industry. The faculty covered topics ranging from the activities of the Massachusetts Life Sciences Center in its administration of the $1 billion Life Sciences Initiative, to the key issues for parties in spinouts of life sciences companies from hospitals and universities, to critical concerns related to IP due diligence in transactions involving life sciences companies, to the evolution of patent declaratory judgment case law in the post-MedImmune era.
For more information, please visit the MCLE Event page.